UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A GMCSF-neuroantigen fusion protein is a potent tolerogen in experimental autoimmune encephalomyelitis (EAE) that is associated with efficient targeting of neuroantigen to APC

Journal of leukocyte biology, 2010-03, Vol.87 (3), p.509-521

2010

Volltextzugriff (PDF)

Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2)

Journal for immunotherapy of cancer, 2024-08, Vol.12 (8), p.e009474

2024

Volltextzugriff (PDF)

Dual Molecular Mechanisms Govern Escape at Immunodominant HLA A2-Restricted HIV Epitope

Frontiers in immunology, 2017-11, Vol.8, p.1503-1503

2017

Volltextzugriff (PDF)

S276: POVETACICEPT (ALPN‐303), A POTENT DUAL BAFF/APRIL ANTAGONIST, FOR THE TREATMENT OF AUTOIMMUNE CYTOPENIAS AND OTHER ANTIBODY‐RELATED DISEASES

HemaSphere, 2023-08, Vol.7 (S3), p.e3301055-n/a

2023

Volltextzugriff (PDF)

Responders to low-dose ATG induce CD4+ T cell exhaustion in type 1 diabetes

JCI insight, 2023-08, Vol.8 (16)

2023

Volltextzugriff (PDF)

Cytokine-neuroantigen fusion proteins as a new class of tolerogenic, therapeutic vaccines for treatment of inflammatory demyelinating disease in rodent models of multiple sclerosis

Frontiers in immunology, 2012-01, Vol.3, p.255-255

2012

Volltextzugriff (PDF)

Monitoring the Dynamics of T Cell Clonal Diversity Using Recombinant Peptide:MHC Technology

Frontiers in immunology, 2013-01, Vol.4, p.170-170

2013

Volltextzugriff (PDF)

33 Development of a clinical ex vivo assay for the assessment of therapeutic CD28 costimulatory pathway engagement

Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A39-A39

2021

Volltextzugriff (PDF)

Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA1c, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data

Diabetes (New York, N.Y.), 2019-06, Vol.68 (6), p.1267-1276

2019

Volltextzugriff (PDF)

Experimental autoimmune encephalomyelitis in Lewis rats: IFN-beta acts as a tolerogenic adjuvant for induction of neuroantigen-dependent tolerance

The Journal of immunology (1950), 2009-05, Vol.182 (9), p.5331-5341

2009

Volltextzugriff (PDF)

Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

The lancet. Diabetes & endocrinology, 2021-08, Vol.9 (8), p.502-514

2021

Volltextzugriff (PDF)

DNA-based nanoparticle tension sensors reveal that T-cell receptors transmit defined pN forces to their antigens for enhanced fidelity

Proceedings of the National Academy of Sciences - PNAS, 2016-05, Vol.113 (20), p.5610-5615

2016

Volltextzugriff (PDF)

Guidelines for standardizing T‐cell cytometry assays to link biomarkers, mechanisms, and disease outcomes in type 1 diabetes

European journal of immunology, 2022-03, Vol.52 (3), p.372-388

2022

Volltextzugriff (PDF)

Neuroantigen-specific, tolerogenic vaccines: GM-CSF is a fusion partner that facilitates tolerance rather than immunity to dominant self-epitopes of myelin in murine models of experimental autoimmune encephalomyelitis (EAE)

BMC immunology, 2011-12, Vol.12 (1), p.72-72, Article 72

2011

Volltextzugriff (PDF)

Distinct waves of CD8 T cell affinity during demyelinating disease progression

The Journal of immunology (1950), 2019-05, Vol.202 (1_Supplement), p.115-115.18

2019

Volltextzugriff (PDF)

CD4 + T affinity and cross-reactivity between MOG and NFM during the polyclonal response of MOG induced demyelinating autoimmune disease

Journal of neuroimmunology, 2014-01, Vol.275 (1), p.196-197

2014

Volltextzugriff (PDF)

42273 Phase 1 Study in Healthy Adults of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALPN-303, a Dual BAFF/APRIL Antagonist for the Treatment of Autoimmune Blistering Diseases

Journal of the American Academy of Dermatology, 2023-09, Vol.89 (3), p.AB74-AB74

2023

Volltextzugriff (PDF)

Ratiometric Tension Probes for Mapping Receptor Forces and Clustering at Intermembrane Junctions

Nano letters, 2016-07, Vol.16 (7), p.4552-4559

2016

Volltextzugriff (PDF)

4024 PHASE 1 STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF POVETACICEPT FOR AUTOIMMUNE GLOMERULONEPHRITIDES

Nephrology, dialysis, transplantation, 2023-06, Vol.38 (Supplement_1)

2023

Volltextzugriff (PDF)

A Randomized, Placebo-Controlled, Phase 1 Study in Healthy Adult Volunteers of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALPN303, a Potent Dual BAFF/APRIL Antagonist for the Treatment of Autoimmune Cytopenias

Blood, 2022-11, Vol.140 (Supplement 1), p.8401-8403

2022

Volltextzugriff (PDF)

NFM Cross-Reactivity to MOG Does Not Expand a Critical Threshold Level of High-Affinity T Cells Necessary for Onset of Demyelinating Disease

The Journal of immunology (1950), 2017-10, Vol.199 (8), p.2680-2691

2017

Volltextzugriff (PDF)

Ratiometric Tension Probes for Mapping Receptor Forces and Clustering at Intermembrane Junctions

Biophysical journal, 2017-02, Vol.112 (3), p.593a-593a

2017

Volltextzugriff (PDF)

Tissue-specific antigens induce dual complementary T cell tolerance mechanisms

The Journal of immunology (1950), 2016-05, Vol.196 (1_Supplement), p.55-55.6

2016

Volltextzugriff (PDF)

TCR affinity and tolerance mechanisms converge to shape T cell diabetogenic potential

The Journal of immunology (1950), 2014-07, Vol.193 (2), p.571-579

2014

Volltextzugriff (PDF)

MOG35-55, not NFM15-35, is the critical autoantigen for inducing demyelinating autoimmune disease

The Journal of immunology (1950), 2017-05, Vol.198 (1_Supplement), p.156-156.28

2017

Volltextzugriff (PDF)

1 – 25 von 44

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(42)
Mit Volltextzugriff
(40)

Publikationsform

Artikel
(43)
Dissertationen
(1)

Sprache

Englisch
(44)

Erscheinungsjahr

n.n

Thema

Science & Technology
(18)
Life Sciences & Biomedicine
(15)
Immunology
(12)
Humans
(10)
Animals
(8)
Female
(5)
Mice
(5)
Encephalomyelitis, Autoimmune, Experimental - Immunology
(4)
Flow Cytometry
(4)
Adult
(3)
Clinical Trials
(3)
Diabetes Mellitus, Type 1 - Drug Therapy
(3)
Male
(3)
Recombinant Fusion Proteins - Immunology
(3)
Science & Technology - Other Topics
(3)
Adolescent
(2)
Amino Acid Sequence
(2)
Antigens
(2)
Antilymphocyte Serum - Therapeutic Use
(2)
Aquatic Ecosystems
(2)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

A GMCSF-neuroantigen fusion protein is a potent tolerogen in experimental autoimmune encephalomyelitis (EAE) that is associated with efficient targeting of neuroantigen to APC

Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2)

Dual Molecular Mechanisms Govern Escape at Immunodominant HLA A2-Restricted HIV Epitope

S276: POVETACICEPT (ALPN‐303), A POTENT DUAL BAFF/APRIL ANTAGONIST, FOR THE TREATMENT OF AUTOIMMUNE CYTOPENIAS AND OTHER ANTIBODY‐RELATED DISEASES

Responders to low-dose ATG induce CD4+ T cell exhaustion in type 1 diabetes

Cytokine-neuroantigen fusion proteins as a new class of tolerogenic, therapeutic vaccines for treatment of inflammatory demyelinating disease in rodent models of multiple sclerosis

Monitoring the Dynamics of T Cell Clonal Diversity Using Recombinant Peptide:MHC Technology

33 Development of a clinical ex vivo assay for the assessment of therapeutic CD28 costimulatory pathway engagement

Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA1c, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data

Experimental autoimmune encephalomyelitis in Lewis rats: IFN-beta acts as a tolerogenic adjuvant for induction of neuroantigen-dependent tolerance

Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

DNA-based nanoparticle tension sensors reveal that T-cell receptors transmit defined pN forces to their antigens for enhanced fidelity

Guidelines for standardizing T‐cell cytometry assays to link biomarkers, mechanisms, and disease outcomes in type 1 diabetes

Neuroantigen-specific, tolerogenic vaccines: GM-CSF is a fusion partner that facilitates tolerance rather than immunity to dominant self-epitopes of myelin in murine models of experimental autoimmune encephalomyelitis (EAE)

Distinct waves of CD8 T cell affinity during demyelinating disease progression

CD4 + T affinity and cross-reactivity between MOG and NFM during the polyclonal response of MOG induced demyelinating autoimmune disease

42273 Phase 1 Study in Healthy Adults of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALPN-303, a Dual BAFF/APRIL Antagonist for the Treatment of Autoimmune Blistering Diseases

Ratiometric Tension Probes for Mapping Receptor Forces and Clustering at Intermembrane Junctions

4024 PHASE 1 STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF POVETACICEPT FOR AUTOIMMUNE GLOMERULONEPHRITIDES

A Randomized, Placebo-Controlled, Phase 1 Study in Healthy Adult Volunteers of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALPN303, a Potent Dual BAFF/APRIL Antagonist for the Treatment of Autoimmune Cytopenias

NFM Cross-Reactivity to MOG Does Not Expand a Critical Threshold Level of High-Affinity T Cells Necessary for Onset of Demyelinating Disease

Ratiometric Tension Probes for Mapping Receptor Forces and Clustering at Intermembrane Junctions

Tissue-specific antigens induce dual complementary T cell tolerance mechanisms

TCR affinity and tolerance mechanisms converge to shape T cell diabetogenic potential

MOG35-55, not NFM15-35, is the critical autoantigen for inducing demyelinating autoimmune disease

Suchergebnisse filtern